Editorial on Niacin 2-2015
- Angiographic trials from the 1990s provide valuable information on the impact of LDL cholesterol reduction on atherosclerosis progression.
- The CLAS (Cholesterol Lowering Atherosclerosis Study) angiographic trial tested niacin/colestipol therapy in the pre-statin era.
- Visually appreciable angiographic progression was dramatically reduced with niacin/colestipol therapy in the CLAS trial.
- Niacin is a viable therapeutic option for patients who are statin intolerant or who need additional LDL reduction after maximum statin therapy fails to achieve adequate reduction.